Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...

An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the ...

The clinical characteristics of ACLD overlap most notably with several other conditions including Mycosis Fungoides/Sézary Syndrome (MF/SS), a cutaneous lymphoma of T-cell lineage. Unlike Mycosis ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL ...

Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma.

LYL314 is an autologous dual-targeting CAR T-cell therapy aimed at treating relapsed and refractory large B-cell lymphoma. What were the clinical response rates for LYL314?

Secondary Cancer Risk Rises After Cutaneous B-Cell Lymphoma Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a recent study.

Cellular therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), have revolutionized the treatment of various B-cell non-Hodgkin lymphomas. A number of agents ...

In this study, we assessed the safety, feasibility, and preliminary efficacy of huCART19-IL18 in patients with relapsed or refractory lymphoma after previous anti-CD19 CAR T-cell therapy. Using a ...

Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a recent study.